

Supplementary Table 9. Prevalence of *MET* tyrosine kinase domain (TKD) mutations across tumor in “other cancers” from Supplementary Table 8.

Cancer Type	Oncogenic / likely oncogenic <i>MET</i> TKD mutations (N)	Oncogenic / likely oncogenic <i>MET</i> TKD mutations (%)	<i>MET</i> TKD mutations of unknown biological function (N)	<i>MET</i> TKD mutations of unknown biological function (%)	Total <i>MET</i> TKD mutations (N)	Total <i>MET</i> TKD mutations (%)	Total (N)
Endocrine	1	0.05	8	0.40	9	0.45	2,011
Lung Cancer NOS	2	0.10	17	0.89	19	0.99	1,918
Pituitary Gland	0	0	1	1.67	1	1.67	60
Thymus	0	0	3	0.64	3	0.64	466
Salivary Gland	1	0.06	7	0.41	8	0.47	1,720
Peripheral Nervous System	0	0	2	0.30	2	0.30	675
Germ Cell	0	0	2	0.29	2	0.29	696
Peritoneum	0	0	3	0.21	3	0.21	1,412
Adenoid Cystic Carcinoma	1	0.06	2	0.13	3	0.19	1,551
Adrenal Gland	0	0	1	0.15	1	0.15	672
Thyroid	0	0	4	0.11	4	0.11	3,779
Carcinoid	0	0	1	0.10	1	0.10	983
Mesothelioma	0	0	1	0.06	1	0.06	1,682

Abbreviation: NOS, not otherwise specified